Shionogi is seeking Japanese approval for a new lotion formulation of its atopic dermatitis drug, designed for easier application and improved patient adherence. This user-centric approach aims to enhance treatment outcomes and strengthen Shionogi's position in the dermatology market.
The introduction of a lotion formulation for CORECTIM® addresses a practical need for atopic dermatitis patients, particularly for application on the scalp and other hairy areas. This user-centric formulation is designed to improve treatment adherence by offering a more cosmetically acceptable and convenient option than traditional ointments. Enhanced patient compliance could lead to better treatment outcomes and solidify Shionogi's market position in Japan's competitive dermatology sector.
Shionogi applies for Japanese approval of a new lotion form of its atopic dermatitis drug
The lotion is bioequivalent to the existing ointment but offers a more convenient application
The new formulation is expected to improve patient adherence and quality of life
The new formulation is expected to improve patient adherence and quality of life
Shionogi applies for Japanese approval of a new lotion form of its atopic dermatitis drug
Sign in to save notes on signals.
Sign In